AU1102401A - Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products - Google Patents
Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin productsInfo
- Publication number
- AU1102401A AU1102401A AU11024/01A AU1102401A AU1102401A AU 1102401 A AU1102401 A AU 1102401A AU 11024/01 A AU11024/01 A AU 11024/01A AU 1102401 A AU1102401 A AU 1102401A AU 1102401 A AU1102401 A AU 1102401A
- Authority
- AU
- Australia
- Prior art keywords
- antigen
- cancers
- express
- reducing
- effects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/425,638 US6342587B1 (en) | 1999-10-22 | 1999-10-22 | A33 antigen specific immunoglobulin products and uses thereof |
US09425638 | 1999-10-22 | ||
US09543004 | 2000-04-04 | ||
US09/543,004 US6346249B1 (en) | 1999-10-22 | 2000-04-04 | Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products |
PCT/US2000/029289 WO2001030393A2 (en) | 1999-10-22 | 2000-10-20 | Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products |
Publications (1)
Publication Number | Publication Date |
---|---|
AU1102401A true AU1102401A (en) | 2001-05-08 |
Family
ID=27026757
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU11024/01A Abandoned AU1102401A (en) | 1999-10-22 | 2000-10-20 | Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products |
AU10973/01A Abandoned AU1097301A (en) | 1999-10-22 | 2000-10-20 | Humanization of non-human, mammalian antibodies |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU10973/01A Abandoned AU1097301A (en) | 1999-10-22 | 2000-10-20 | Humanization of non-human, mammalian antibodies |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1233790A2 (en) |
JP (1) | JP2003527334A (en) |
AU (2) | AU1102401A (en) |
WO (1) | WO2001030393A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1102401A (en) * | 1999-10-22 | 2001-05-08 | Ludwig Institute For Cancer Research | Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products |
US6652853B2 (en) * | 2001-03-08 | 2003-11-25 | Ludwig Institute For Cancer Research | Method for treating cancer using A33 specific antibodies and chemotherapeutic agents |
WO2003016909A1 (en) * | 2001-08-16 | 2003-02-27 | Ludwig Institute For Cancer Research | Method for determining protein component in a biological sample |
KR100918746B1 (en) * | 2004-09-06 | 2009-09-24 | 교와 핫꼬 기린 가부시키가이샤 | Anti-a33 antibody |
SG194368A1 (en) | 2007-05-04 | 2013-11-29 | Technophage Investigacao E Desenvolvimento Em Biotecnologia Sa | Engineered rabbit antibody variable domains and uses thereof |
TWI609965B (en) * | 2007-05-21 | 2018-01-01 | 艾爾德生物控股有限責任公司 | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
CN104961828B (en) * | 2008-06-25 | 2019-03-26 | 艾斯巴技术-诺华有限责任公司 | Inhibit the stabilization and soluble antibodies of VEGF |
TR201808591T4 (en) | 2008-06-25 | 2018-07-23 | Esbatech Alcon Biomed Res Unit | Humanization of rabbit antibodies using a universal antibody skeleton. |
WO2013186719A1 (en) * | 2012-06-15 | 2013-12-19 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
RU2019138507A (en) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | ANTIBODY AGAINST LAG3 AND JOINT ANTIBODY AGAINST LAG3 AND ANTIBODY AGAINST PD-1 |
JOP20190260A1 (en) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
KR20210089215A (en) * | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | Co-Formulation of Anti-LAG3 Antibody and Anti-PD-1 Antibody |
CN110540591A (en) * | 2019-08-09 | 2019-12-06 | 无锡傲锐东源生物科技有限公司 | anti-Glycoprotein A33 (glycoprotin A33) monoclonal antibody and immunodetection application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6190640B1 (en) * | 1985-04-19 | 2001-02-20 | Ludwig Institute For Cancer Research | Method for treating neoplasia using humanized antibodies which bind to antigen A33 |
ATE214734T1 (en) * | 1992-12-10 | 2002-04-15 | Celltech Therapeutics Ltd | HUMANIZED ANTIBODIES DIRECTED AGAINST THE A33 ANTIGEN |
AU1102401A (en) * | 1999-10-22 | 2001-05-08 | Ludwig Institute For Cancer Research | Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products |
US6652853B2 (en) * | 2001-03-08 | 2003-11-25 | Ludwig Institute For Cancer Research | Method for treating cancer using A33 specific antibodies and chemotherapeutic agents |
-
2000
- 2000-10-20 AU AU11024/01A patent/AU1102401A/en not_active Abandoned
- 2000-10-20 JP JP2001532810A patent/JP2003527334A/en not_active Withdrawn
- 2000-10-20 AU AU10973/01A patent/AU1097301A/en not_active Abandoned
- 2000-10-20 EP EP00972349A patent/EP1233790A2/en not_active Withdrawn
- 2000-10-20 WO PCT/US2000/029289 patent/WO2001030393A2/en active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
WO2001030393A2 (en) | 2001-05-03 |
JP2003527334A (en) | 2003-09-16 |
AU1097301A (en) | 2001-05-08 |
EP1233790A2 (en) | 2002-08-28 |
WO2001030393A8 (en) | 2002-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU1462300A (en) | Human pan-hcv human monoclonal antibodies | |
AU4314900A (en) | Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same | |
AU6266899A (en) | Methods for producing human tumor antigen specific antibodies | |
AU1290001A (en) | Antibodies | |
ZA964614B (en) | Methods for the preparation of substantially monomeric callcheamicin derivative carrier conjugates. | |
AU4992997A (en) | Humanized anti-cd11a antibodies | |
ZA968957B (en) | Process for the preparation of dihaloazolopyrimidines. | |
AU3546400A (en) | Tandem immuno-assay for cancer | |
IL121437A0 (en) | Process for the preparation of nootkatone | |
AU5686698A (en) | Methods for the production of chicken monoclonal antibodies | |
AU1102401A (en) | Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products | |
AU7287598A (en) | Process for the conversion of hydrocarbons | |
AU6702998A (en) | Anti-alphabeta3 humanized monoclonal antibodies | |
AU5441000A (en) | Human monoclonal antibody | |
AU6975900A (en) | Rapid colouring process for aluminum products | |
AU4859200A (en) | Process for enhancing the value of hydrocarbonaceous natural resources | |
AU7363000A (en) | Method for reducing the risk of cancer | |
AU6542898A (en) | Sialyl lewis antigens as targets for immunotherapy | |
AU2236201A (en) | Compositions and methods for regulating tumor-associated antigen expression | |
AU7129796A (en) | Apparatus For The Dosed, Air-Ttransported Distribution Of Substances | |
AU3283500A (en) | Tumor-associated antigen | |
AU7572198A (en) | Tumor-associated antigen | |
AU6596400A (en) | Apparatus for producing radioisotope | |
AU7059296A (en) | NK-1 receptor antagonists for the treatment of cancer | |
AU5486396A (en) | Process for the preparation of spiroindolines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |